MRNS: Marinus Pharmaceuticals Inc Company Profile & Statistics

About

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.

Info & Links

CEO

Scott Braunstein

Headquarters

5 Radnor Corporate Center, Suite 500
Radnor, PA 19087, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

166

Marinus Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization²

17.47M

Enterprise Value

69.68M

Enterprise Value/EBITDA(ttm)

-0.57

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

0.40

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

90.08%

Operating Margin(ttm)

-440.29%

Profit Margin(ttm)

-453.22%

Return on Equity(ttm)

-7831.35%

Return on Invested Capital(ttm)

-416.03%

Return on Assets(ttm)

-120.74%

Income Statement

Revenue(ttm)

31.47M

Revenue Per Share(ttm)

0.57

Gross Profit(ttm)

28.37M

EBITDA(ttm)³

-122.68M

Net Income Available to Common(ttm)

-140.49M

Diluted EPS(ttm)

-2.47

Share Statistics

Beta (5Y Monthly)

1.25

52-Week Change

-95.78%

S&P 500 52-Week Change

26.47%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

55.19M

Dividend Yield

0.00%

Float⁴

52.17M

% Held by Insiders

5.46%

% Held by Institutions

98.80%

Balance Sheet

Total Cash(mrq)

42.18M

Total Cash Per Share(mrq)

0.76

Total Debt(mrq)

94.39M

Total Debt/Equity(mrq)

-141.43%

Current Ratio(mrq)

1.66%

Quick Ratio(mrq)

1.47%

Book Value Per Share(mrq)

-1.21

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.53

Free Cash Flow(ytd)

-88.91M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

MRNS

Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc Profile